Hostname: page-component-7479d7b7d-pfhbr Total loading time: 0 Render date: 2024-07-12T00:03:07.123Z Has data issue: false hasContentIssue false
  • English
  • Français

Efficacy and tolerability Aripiprazole once-monthly long-acting injectable in schizophrenia. Two-injection start regimen

Published online by Cambridge University Press:  01 September 2022

S.L. Romero Guillena ,
B.O. Plasencia Garcia De Diego ,
F. Gotor Sanchez-Luengo  and
J. Gómez González
S.L. Romero Guillena*
Affiliation:
UGC Salud Mental Virgen Macarena, , Psychiatry, seville, Spain
B.O. Plasencia Garcia De Diego
Affiliation:
Virgen del Rocio Hospital, Psychiatry, Seville, Spain
F. Gotor Sanchez-Luengo
Affiliation:
Virgen del Rocio Hospital, Psychiatry, Seville, Spain
J. Gómez González
Affiliation:
UGC Salud Mental Virgen Macarena, , Psychiatry, seville, Spain
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Aripiprazole once-monthly is a long-acting intramuscular injectable formulation of aripiprazole. The starting dose can be administered by following one of two regimens: • One injection start: On the day of initiation, administer one injection of 400 mg Aripiprazole once monthly and continue treatment with 10 mg to 20 mg oral aripiprazole per day for 14 consecutive days • Two injection start (New regimen): On the day of initiation, administer two separate injections of 400 mg Aripiprazole once monthly at separate injection sites, along with one 20 mg dose of oral aripiprazole.

Objectives

To assess the effectiveness and tolerability of Aripiprazole long-acting injectable (ALAI) in patients with schizophrenia. The starting dose was administered following the two injection start regimen

Methods

Sample:10 patients with schizophrenia (DSM 5 criteria) who started treatment with ALAI. The starting dose was administered following the two injection start regimen. On a tri-monthly basis, the following evaluations were performed during a follow-up period of 6 months: The Clinical Global Impression-Schizophrenia scale (CGI-SCH), treatment adherence, the number of hospitalizations and Side effects reported

Results

Mean variations from baseline scores at 6 months was (-1.1 ±0.89) on the GCI-SCH. The percentage of patients who remained free of admissions at the end of the 6 months was 90%. The rate of adherence to treatment after 6 months was 80%. The most frequent side effect was transient mild insomnia (20%) .

Conclusions

Aripiprazole long-acting injectable (The starting dose was administered following the two injection start regimen) is effective, safe and well tolerated in clinical practice conditions

Disclosure

No significant relationships.

Keywords

EfficacyschizophréniaAripiprazole once-monthlyTwo-injection start regimen
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S788 - S789
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.